Events

Visit Us at Cirse Visit Us at Cirse

News

July 18, 2017 

Boston Scientific announces favorable 12-month data for Ranger™ Boston Scientific announces favorable 12-month data for Ranger™

Boston Scientific announces RANGER™ Drug-Coated Balloon new Long Lenghts.

The Ranger™ Drug-Coated Balloon is now available in long lengths up to 200mm. Simplify your SFA procedures by treating long lesions with a single DCB! Find out more about Ranger Long Length.

RANGER™ Product Information

 

April 25, 2017 

Boston Scientific announces favorable 12-month data for Ranger™ Boston Scientific announces favorable 12-month data for Ranger™

Boston Scientific announces favorable 12-month data for Ranger

Boston Scientific today announced results from the RANGER SFA trial for the Ranger™ Paclitaxel-Coated PTA Balloon Catheter at the Charing Cross Symposium, in London. Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.


January 31, 2017

 

Boston Scientific drives the DET debate at LINC 2017 symposium Boston Scientific drives the DET debate at LINC 2017 symposium

Boston Scientific drives the DET debate at LINC 2017 symposium

Boston Scientific Drug-Eluting Technology was among the highlights at LINC 2017 with a comprehensive symposium on redefining SFA treatment and discussions on key topics such as its bold clinical trial program and the prospects for drug-eluting technology in Europe.


September 1, 2016

Sustained drug-release may hold the key to long-term efficacy in the SFA Sustained drug-release may hold the key to long-term efficacy in the SFA

Sustained drug-release may hold the key to long-term efficacy in the SFA

Prof. Stefan Muller-Hulsbeck, principal investigator of the MAJESTIC clinical trial, provides his expert opinion on the importance of sustained drug-release in the treatment of SFA lesions.


August 23, 2016

Eluvia demonstrates better inhibition of neointimal formation compared to BMS Eluvia demonstrates better inhibition of neointimal formation compared to BMS

Eluvia demonstrates better inhibition of neointimal formation compared to BMS

Results from a preclinical study evaluating the arterial response to paclitaxel and showed that the Eluvia stent was better at inhibiting neointimal formation compared to bare-metal stents.


February 22, 2016

Eluvia Drug-Eluting Vascular Stent receives CE Mark Eluvia Drug-Eluting Vascular Stent receives CE Mark

Eluvia Drug-Eluting Vascular Stent receives CE Mark

Boston Scientific has received CE Mark for the Eluvia Drug-Eluting Vascular Stent and announces the initiation of the IMPERIAL head-to-head clinical trial comparing Eluvia to the Zilver PTX drug-coated stent.